Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia ...
MELBOURNE, Australia, July 1, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen by an independent group of researchers. The Nature Index provides absolute Count of ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The CSL Behring and Science Center partnership is aimed at ...
The ATS Research Program is pleased to announce that William Zhang, MD, of Weill Cornell Medical Center is the recipient of the 2020-2021 ATS/CSL Behring Research Award in Acute Respiratory Distress ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company advancing a new class of immunotherapies, today announced that it has entered into ...
No articles found. CSL Behring did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly owned, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results